-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 21, the Yunnan Provincial Centralized Drug Purchasing Platform issued a public announcement about companies applying for price reductions
.
The notice shows that Yunnan Mining Center has received active price reduction applications from 21 companies including Shanghai Pharmaceutical Holdings, Chia Tai Tianqing, Jiangsu Hansen, and CSPC.
The prices of 78 medicines including Sedronate Sodium Tablets, Penicillin V Potassium Tablets, Paclitaxel Injection, and Lenvatinib Mesylate Capsules were reduced
.
Judging from the range of price reductions, there are many varieties with larger declines
.
For example, Bengbu Fengyuan Tushan Pharmaceutical's 150mg ranitidine hydrochloride capsules dropped from 45 yuan to 22.
49 yuan, a drop of as much as 50%
.
For another example, the 60mg specification of carfilzomib for injection of Shanghai Pharmaceutical Holdings has dropped from the original 16450 application to 8398 yuan, a decrease of nearly half, reaching about 49%; Shanghai Huilun Jiangsu Pharmaceutical's dienogest tablet 2mg specification The original purchase price limit was 418 yuan, and the company applied for a price reduction of 249 yuan, a drop of 40%
.
In addition, the 16.
7ml:100mg and 5ml:30mg specifications of Huiyu Pharmaceutical's paclitaxel injection have been greatly reduced in price, of which the 16.
7ml:100mg specification has dropped from the original 346 yuan to 185.
5 yuan, and the 5ml:30mg specification has dropped from 137.
65 yuan to 73.
8 yuan , the declines were 46% and 63% respectively
.
It is understood that paclitaxel injection is a plant antitumor drug, used for the first- and second-line treatment of ovarian cancer, breast cancer and non-small cell lung cancer (NSCLC).
Ho Jin's lymphoma, etc.
have a certain effect
.
It is worth mentioning that this product is the fifth batch of selected drugs for national centralized procurement.
The selected companies include Huiyu Pharmaceutical, Yangzijiang Pharmaceutical, Wuxi Yew Pharmaceutical, and the original research company Bristol-Myers Squibb is out
.
According to Huiyu Pharmaceutical's reply on the interactive platform not long ago, its paclitaxel injection has won the bid in Beijing, Tianjin, Hebei, Inner Mongolia, Zhejiang, Guangdong, Guangxi, Tibet, Shaanxi, Xinjiang (including the Corps), and the bidding period is until October 2023.
moon
.
According to data from Minet.
com, in 2019, the terminal sales of paclitaxel in public medical institutions in China exceeded 7.
5 billion yuan, of which paclitaxel for injection (albumin-bound) accounted for 38.
60% of the market share, paclitaxel for injection accounted for 38.
06%, and paclitaxel injection accounted for 38.
06%.
Liquid accounted for 23.
34%
.
In 2020H1, the sales of terminal paclitaxel in Chinese public medical institutions exceeded 3.
5 billion yuan, a year-on-year increase of 8.
56%
.
It can be seen that the market space of paclitaxel injection is relatively huge
.
Judging from Huiyu Pharmaceutical's initiative to reduce prices in Yunnan Province, a non-bid-winning area, under the normalization of centralized procurement, in addition to price reductions for selected varieties, price reductions for non-bid-winning areas have also become a major trend
.
In recent years, many places have also encouraged price cuts for non-selected drugs
.
For example, on February 10, the Liaoning Provincial Centralized Purchasing Network for Drugs and Medical Consumables issued the "Notice on Announcement and Implementation of the Fifth Batch of State-Organized Centralized Drug Purchasing Results of the Gradient Price Reduction Results of Unselected Drugs".
The batch of drugs that were not selected for centralized procurement of drugs organized by the state was announced, including aripiprazole tablets from Huahai Pharmaceutical, acyclovir tablets from Shandong Luoxin, and oxaliplatin for injection from Chia Tai Tianqing.
The result of price reduction It will be implemented from 0:00 on February 14, 2022
.
In addition, for 420 products whose self-declared prices do not meet the gradient price reduction standards, online purchases will be suspended
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
The notice shows that Yunnan Mining Center has received active price reduction applications from 21 companies including Shanghai Pharmaceutical Holdings, Chia Tai Tianqing, Jiangsu Hansen, and CSPC.
The prices of 78 medicines including Sedronate Sodium Tablets, Penicillin V Potassium Tablets, Paclitaxel Injection, and Lenvatinib Mesylate Capsules were reduced
.
Judging from the range of price reductions, there are many varieties with larger declines
.
For example, Bengbu Fengyuan Tushan Pharmaceutical's 150mg ranitidine hydrochloride capsules dropped from 45 yuan to 22.
49 yuan, a drop of as much as 50%
.
For another example, the 60mg specification of carfilzomib for injection of Shanghai Pharmaceutical Holdings has dropped from the original 16450 application to 8398 yuan, a decrease of nearly half, reaching about 49%; Shanghai Huilun Jiangsu Pharmaceutical's dienogest tablet 2mg specification The original purchase price limit was 418 yuan, and the company applied for a price reduction of 249 yuan, a drop of 40%
.
In addition, the 16.
7ml:100mg and 5ml:30mg specifications of Huiyu Pharmaceutical's paclitaxel injection have been greatly reduced in price, of which the 16.
7ml:100mg specification has dropped from the original 346 yuan to 185.
5 yuan, and the 5ml:30mg specification has dropped from 137.
65 yuan to 73.
8 yuan , the declines were 46% and 63% respectively
.
It is understood that paclitaxel injection is a plant antitumor drug, used for the first- and second-line treatment of ovarian cancer, breast cancer and non-small cell lung cancer (NSCLC).
Ho Jin's lymphoma, etc.
have a certain effect
.
It is worth mentioning that this product is the fifth batch of selected drugs for national centralized procurement.
The selected companies include Huiyu Pharmaceutical, Yangzijiang Pharmaceutical, Wuxi Yew Pharmaceutical, and the original research company Bristol-Myers Squibb is out
.
According to Huiyu Pharmaceutical's reply on the interactive platform not long ago, its paclitaxel injection has won the bid in Beijing, Tianjin, Hebei, Inner Mongolia, Zhejiang, Guangdong, Guangxi, Tibet, Shaanxi, Xinjiang (including the Corps), and the bidding period is until October 2023.
moon
.
According to data from Minet.
com, in 2019, the terminal sales of paclitaxel in public medical institutions in China exceeded 7.
5 billion yuan, of which paclitaxel for injection (albumin-bound) accounted for 38.
60% of the market share, paclitaxel for injection accounted for 38.
06%, and paclitaxel injection accounted for 38.
06%.
Liquid accounted for 23.
34%
.
In 2020H1, the sales of terminal paclitaxel in Chinese public medical institutions exceeded 3.
5 billion yuan, a year-on-year increase of 8.
56%
.
It can be seen that the market space of paclitaxel injection is relatively huge
.
Judging from Huiyu Pharmaceutical's initiative to reduce prices in Yunnan Province, a non-bid-winning area, under the normalization of centralized procurement, in addition to price reductions for selected varieties, price reductions for non-bid-winning areas have also become a major trend
.
In recent years, many places have also encouraged price cuts for non-selected drugs
.
For example, on February 10, the Liaoning Provincial Centralized Purchasing Network for Drugs and Medical Consumables issued the "Notice on Announcement and Implementation of the Fifth Batch of State-Organized Centralized Drug Purchasing Results of the Gradient Price Reduction Results of Unselected Drugs".
The batch of drugs that were not selected for centralized procurement of drugs organized by the state was announced, including aripiprazole tablets from Huahai Pharmaceutical, acyclovir tablets from Shandong Luoxin, and oxaliplatin for injection from Chia Tai Tianqing.
The result of price reduction It will be implemented from 0:00 on February 14, 2022
.
In addition, for 420 products whose self-declared prices do not meet the gradient price reduction standards, online purchases will be suspended
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
